Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

COVID-19 and vaping: risk for increased susceptibility to SARS-CoV-2 infection?

Kielan Darcy McAlinden, Mathew Suji Eapen, Wenying Lu, Collin Chia, Greg Haug, Sukhwinder Singh Sohal
European Respiratory Journal 2020 56: 2001645; DOI: 10.1183/13993003.01645-2020
Kielan Darcy McAlinden
1Respiratory Translational Research Group, Department of Laboratory Medicine, School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathew Suji Eapen
1Respiratory Translational Research Group, Department of Laboratory Medicine, School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mathew Suji Eapen
Wenying Lu
1Respiratory Translational Research Group, Department of Laboratory Medicine, School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Collin Chia
1Respiratory Translational Research Group, Department of Laboratory Medicine, School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Australia
2Department of Respiratory Medicine, Launceston General Hospital, Launceston, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Greg Haug
1Respiratory Translational Research Group, Department of Laboratory Medicine, School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Australia
2Department of Respiratory Medicine, Launceston General Hospital, Launceston, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sukhwinder Singh Sohal
1Respiratory Translational Research Group, Department of Laboratory Medicine, School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Absolute cessation of any tobacco product in any form: implications for COVID-19 https://bit.ly/3cyk9ra

To the Editor:

With great interest we read and commend the study done by Russo et al. [1], highlighting their findings that nicotine induces an increase in angiotensin-converting enzyme 2 (ACE-2) expression in human bronchial epithelial cells (HBEpC) and is mediated by α7-subtype nicotinic receptors (α7-nAChR). It raises the concern that all electronic nicotine-delivery systems may put users at greater risk of succumbing to coronavirus disease 2019 (COVID-19).

We [2], along with Leung et al. [3], have shown that ACE-2 expression is upregulated in the small airway epithelia of smokers and patients with COPD. In particular, we observed increased ACE-2 expression in type-2 pneumocytes and alveolar macrophages along with the small airway epithelium of smokers compared to healthy never-smokers [2]. Similar studies are yet to be done in the context of electronic cigarettes (e-cigarettes), heat-not-burn devices (IQOS) or waterpipe exposure to human airways. ACE-2 is the binding site for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), mediating entry of the virus into cells [4]. Binding affinity between the spike proteins of the virus and ACE-2 on respiratory cells has been identified to be much higher than any previously identified human coronavirus. The significance of such overexpression of ACE-2 in smokers should not be ignored. COVID-19 and progression of severe pneumonia may be more likely to occur in smokers, particularly in those that have smoking-related comorbidities [5]. We are beginning to elucidate the role of traditional cigarette smoking and nicotine-driven changes to the lungs in the context of coronavirus transmission and susceptibility. Cigarette smoke has been identified and linked to increasing expression of the binding site for the cause of the 2020 pandemic (SARS-CoV-2) via mediating nicotine receptors. With this, an avoidable and potentially gigantic risk-factor has emerged for COVID-19, as the pandemic continues to claim ultimate grasp over the year of 2020.

Here, we bring to the discussion whether the increased susceptibility and virulence of SARS-CoV-2 via α7-nAChR and the upregulation of small airway ACE-2 expression may also be relevant for those who vape using nicotine-based e-cigarettes. E-cigarette vapour studies, although in their infancy, have already shown that they can enhance the virulence and inflammatory profile of pathogens such as Streptococcus pneumoniae, among other deleterious biological effects [6]. Vaping intensifies pneumococcal adherence through an increase in platelet-activating factor receptor expression, ultimately rendering those who vape with an increased risk of pneumonia [7, 8]. We, among others, have previously shown that e-cigarettes and IQOS are not “safer”, as having a vast pro-inflammatory response [9]. We compared cigarette smoke versus e-cigarette and IQOS on airway epithelial and smooth muscle cells [9]. All tested pathological biomarkers were elevated in cells exposed to e-cigarette aerosols and IQOS, which included chemokine CXCL8, extracellular matrix proteins and markers of mitochondrial dysfunction. We found these products toxic to the cells, evident from decreased cellular viability and integrity. More devastatingly, vaping also interfered with cellular energetics. Our results further substantiate current research that e-cigarettes and IOQS are indeed detrimental with increases in oxidative stress, inflammation, infections and airway remodelling in the lungs of these device users. As the scientific evidence mounts, confirming the fears that e-cigarettes and IQOS are strongly associated with the development and progression of debilitating lung diseases [10], now may be the prime time to include all electronic nicotine delivery systems in the vocalisation of concerns concerning tobacco-related death and disease.

We recirculate the simple notion that the lungs are not designed for the chronic inhalation of anything but air and that the indication for a smoking- and nicotine-induced increase in ACE2 is more evidence to the stacking weight of toxicity that tobacco is for humanity. Given the role of the nicotine receptor, vaping may also lead to the upregulation of ACE-2. Research in this area will be invaluable in the development of e-cigarette research and providing trusted, peer-reviewed and real evidence for the youth of the 2020s. We strongly recommend that the World Health Organization and countries act to advance their efforts to reduce smoking, vaping and waterpipe use. During a pandemic it is difficult to focus on anything other than the immediate threat. The “primacy of rescue” has overwhelmed preventive action. Additional research into the relationship of smoking, and all electronic nicotine delivery systems to the infection, transmission and progression of COVID-19 is required. Progress towards easily identifying those susceptible to severe disease or capable of asymptomatic transmission are important goals for managing the disease at a community level. COVID-19 is a dress rehearsal for the next pandemic, and the next, and the one after that: the new norm.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-01645-2020.Shareable

Acknowledgements

Clifford Craig Foundation Launceston General Hospital, Rebecca L. Cooper Medical Research Foundation.

Footnotes

  • Conflict of interest: K.D. McAlinden has nothing to disclose.

  • Conflict of interest: M.S. Eapen has nothing to disclose.

  • Conflict of interest: W. Lu has nothing to disclose.

  • Conflict of interest: C. Chia has nothing to disclose.

  • Conflict of interest: G. Haug has nothing to disclose.

  • Conflict of interest: S.S. Sohal has nothing to disclose.

  • Received May 7, 2020.
  • Accepted May 10, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Russo P,
    2. Bonassi S,
    3. Giacconi R, et al.
    COVID-19 and smoking: is nicotine the hidden link? Eur Respir J 2020; 55: 2001116. doi:10.1183/13993003.01116-2020
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Brake SJ,
    2. Barnsley K,
    3. Lu W, et al.
    Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19). J Clin Med 2020; 9: 841. doi:10.3390/jcm9030841
    OpenUrl
  3. ↵
    1. Leung JM,
    2. Yang CX,
    3. Tam A, et al.
    ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 2020; 55: 200688. doi:10.1183/13993003.00688-2020
    OpenUrl
  4. ↵
    1. Wrapp D,
    2. Wang N,
    3. Corbett KS, et al.
    Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367: 1260–1263. doi:10.1126/science.abb2507
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Liu W,
    2. Tao Z-W,
    3. Wang L, et al.
    Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J 2020; 133: 1032–1038.
    OpenUrlPubMed
  6. ↵
    1. Gilpin DF,
    2. McGown KA,
    3. Gallagher K, et al.
    Electronic cigarette vapour increases virulence and inflammatory potential of respiratory pathogens. Respir Res 2019; 20: 267. doi:10.1186/s12931-019-1206-8
    OpenUrl
  7. ↵
    1. Miyashita L,
    2. Suri R,
    3. Dearing E, et al.
    E-cigarette vapour enhances pneumococcal adherence to airway epithelial cells. Eur Respir J 2018; 51: 1701592. doi:10.1183/13993003.01592-2017
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Atto B,
    2. Eapen MS,
    3. Sharma P, et al.
    New therapeutic targets for the prevention of infectious acute exacerbations of COPD: role of epithelial adhesion molecules and inflammatory pathways. Clin Sci 2019; 133: 1663–1703. doi:10.1042/CS20181009
    OpenUrl
  9. ↵
    1. Sohal SS,
    2. Eapen MS,
    3. Naidu VGM, et al.
    IQOS exposure impairs human airway cell homeostasis: direct comparison with traditional cigarette and e-cigarette. ERJ Open Res 2019; 5: 00159-2018. doi:10.1183/23120541.00159-2018
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. McAlinden KD,
    2. Sohal SS,
    3. Sharma P
    . There can be smoke without fire: warranted caution in promoting electronic cigarettes and heat not burn devices as a safer alternative to cigarette smoking. ERJ Open Res 2019; 5: 00114-2019. doi:10.1183/23120541.00114-2019
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 56 Issue 1 Table of Contents
European Respiratory Journal: 56 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 and vaping: risk for increased susceptibility to SARS-CoV-2 infection?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
COVID-19 and vaping: risk for increased susceptibility to SARS-CoV-2 infection?
Kielan Darcy McAlinden, Mathew Suji Eapen, Wenying Lu, Collin Chia, Greg Haug, Sukhwinder Singh Sohal
European Respiratory Journal Jul 2020, 56 (1) 2001645; DOI: 10.1183/13993003.01645-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
COVID-19 and vaping: risk for increased susceptibility to SARS-CoV-2 infection?
Kielan Darcy McAlinden, Mathew Suji Eapen, Wenying Lu, Collin Chia, Greg Haug, Sukhwinder Singh Sohal
European Respiratory Journal Jul 2020, 56 (1) 2001645; DOI: 10.1183/13993003.01645-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Correspondence

  • Clinical outcomes of bronchiectasis in India
  • Reply: Clinical outcomes of bronchiectasis in India
  • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society